Accelerated hyperfractionated radiotherapy combined with induction and concomitant chemotherapy for inoperable non-small-cell lung cancer: Impact of total treatment time

Acta Oncologica

Volumn 37, Issue 6, 1998, Pages 539-545

  Nyman, Jan ^a   Bergman, Bengt ^a   Mercke, Claes ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; FUROSEMIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; ESOPHAGITIS; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY;

EID: 0031763129     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418698430232     Document Type: Article

References (29)

1. Shepherd FA. Treatment of advanced non-small cell lung cancer. Semin Oncol 1994; 21: 7-18.
2. Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 1987; 59: 1874-81.
3. Wilson GD, McNally NJ, Dische S, Bennett MH. Cell proliferation in human tumours measured by in vivo labelling with bromodeoxyuridine. Br J Cancer 1988; 6: 419-22.
4. Saunders MI, Dische S. Continuous, hyperfractionated, accelerated radiotherapy (CHART) in non-small-cell carcinoma of the bronchus. Int J Radiat Oncol Biol Phys 1990; 19: 1211-5.
5. Saunders MI, Dische S, Barret A, et al. Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. Br J Cancer 1996; 73: 1455-62.
6. Koukourakis M, Hlouverakis G, Kosma L, et al. The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys 1996; 34: 315-22.
7. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.
8. Dewit L. Combined treatment of radiation and cis-diaminedichloroplatinum (II): A review of experimental and clinical data. Int J Radiat Oncol Biol Phys 1987; 13: 403-26.
9. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992; 326: 524-30.
10. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomised study. J Clin Oncol 1996; 14: 1065-70.
11. Brindle JS, Shaw EG, Su JQ, et al. Pilot study of accelerated hyperfractionated thoracic radiation therapy in patients with unresectable stage III non-small cell lung carcinoma. Cancer 1993; 72: 405-9.
12. World Health Organization. WHO Handbook for reporting the results of cancer treatment. Vol 48. Geneva, 1979.
13. Peto R, Dike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation for each patient. Analysis and examples. Br J Cancer 1977; 35: 1-39.
14. Brodin O, Nou E, Mercke C, et al. Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung. Eur J Cancer 1996; 32A: 1893-900.
15. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: Seven year follow-up of cancer and leukemia Group B 8433 trial. J Natl Cancer Inst 1996; 88: 1210-5.
16. Byhardt RW, Martin L, Pajak TF, et al. The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer - analysis of a radiation therapy oncology group protocol. Int J Radiat Oncol Biol Phys 1993; 27: 537-44.
17. Le Chevallier T, Arriagada R, Quoix E, et al. Radiotherapy alone vs. combined chemotherapy and radiotherapy in nonresectable nonsmall cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83: 417-23.
18. Lee JS, Scott C, Komaki R, et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: RTOG protocol 91-06. J Clin Oncol 1996; 14: 1055-64.
19. Furuse K, Fukuoka Y, Takada H, et al. A randomised phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer: preliminary analysis. Proceedings of ASCO 1997; 16: 459a.
20. Shaw EG, McGinnis WL, Jett JR, et al. Pilot study of accelerated hyperfractionated thoracic radiation therapy plus concomitant etoposide and cisplatin chemotherapy in patients with unresectable stage III non-small-cell carcinoma of the lung. J Natl Cancer Inst 1993; 85: 321-3.
21. Reboul F, Brewer Y, Vincent P, et al. Concurrent cisplatin, etoposide and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study. Int J Radiat Oncol Biol Phys 1996; 35: 343-50.
22. Pitsch J, Berson AM, Malamud S, et al. Chemoradiation in advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1995; 33: 183-8.
23. Alberto P, Mirimanoff RO, Mermillod B, et al. Rapidly alternating combination of cisplatin-based chemotherapy and hyperfractionated accelerated radiotherapy in split course for stage IIIA and stage IIIB non-small-cell lung cancer: results of a phase I-II study by the GOTHA group. Eur J Cancer 1995; 31A: 342-8.
24. Byhardt RW, Scott CB, Ettinger DS, et al. Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Cancer 1995; 75: 2337-44.
25. Le Pe'choux C, Arriagada R, Le Chevalier T, et al. Concurrent cisplatin-vindesine and hyperfractionated thoracic radiotherapy in locally advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1996; 35: 519-25.
26. Ball D, Bishop J, Smith J, et al. Phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer: an interim toxicity analysis of the first 100 patients. Int J Radiat Oncol Biol Phys 1995; 31: 267-72.
27. Ball D, Bishop J, Smith J, et al. A phase III study of conventional and accelerated radiotherapy with and without carboplatin in unresectable non small cell lung cancer. Radiotherapy and Oncology 1996, 40 (Suppl 1): S61, 231.
28. Sause WT, Scott C, Taylor S, et al. RTOG 88-08 and ECOG 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87: 198-205.
29. Feld R, Borges M, Giner V, et al. Prognostic factors in non-small cell lung cancer. Lung Cancer 1994; 11 (Suppl 3): 19-23.